In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants
Our results suggest that several kinase inhibitors, including vatalanib and linsitinib, can cause CYP-mediated drug-drug interactions with warfarin and, to a lesser extent, with apixaban and rivaroxaban. The work provides mechanistic insights into the risk of DDIs between kinase inhibitors and anticoagulants, which can be used to avoid preventable DDIs in the clinic.
Authors
- Mika Kurkela (ORCID: https://orcid.org/0000-0002-4153-4143)
- Shasha Jin (ORCID: https://orcid.org/0000-0002-3658-8219)
- Marie‐Noëlle Paludetto (ORCID: https://orcid.org/0000-0002-8053-6889)
- Janne T. Backman (ORCID: https://orcid.org/0000-0002-9577-2788)
- Helinä Kahma (ORCID: https://orcid.org/0000-0003-1972-7368)
- Xiaoqiang Xiang
- Weimin Cai (ORCID: https://orcid.org/0000-0002-0342-4912)
- Mikko Neuvonen (ORCID: https://orcid.org/0000-0002-7627-1638)
Institutions
- University of Helsinki (FI)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Helsinki University Hospital (FI)
- Renji Hospital (CN)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.ejps.2024.106884
- Citations
- 6
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.80
Funders
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- National Natural Science Foundation of China
- Academy of Finland
- China Scholarship Council
- Sigrid Juséliuksen Säätiö